Prices & performance Investment updates Latest insights Invest now
Prices & performance Investment updates Latest insights Invest now

Antipodes Global Shares (Quoted Managed Fund) (ASX: AGX1)

The Antipodes Global Shares (Quoted Managed Fund) is an exchange traded managed fund quoted on the ASX, otherwise known as an active ETF, that follows the highly-rated strategy of Antipodes Global Fund – Long, offering investors access to a long only global securities portfolio via a single trade.

Our fundamental, pragmatic value-focused approach focuses on buying great but undervalued companies and building a concentrated portfolio of at least 30 holdings. The fund is designed to deliver absolute returns in excess of the benchmark over the long term while protecting our investors from risk and volatility.

Indicative NAV:

per unit as at
May 20, 2022 04:11:59 (pm)

$5.4824
1 second delayed price
NAV:
per unit as at

close of business

Key facts

Global investment opportunities with a single trade

AGX1 provides access to an actively managed portfolio of attractively valued companies listed on global share markets via a single trade. There is no minimum investment and you can trade AGX1 units on the ASX like a normal share. AGX1 typically invests in a minimum of 30 companies listed on global share markets offering investors diversification and differentiated exposure to the benchmark.

Investment objective

To provide shareholders with absolute returns in excess of the benchmark while focusing on capital preservation and maintaining beneath market levels of risk over the long-term.

Antipodes Global Shares (Quoted Managed Fund) - Performance Table

Past performance is not a reliable indicator of future performance. Returns are calculated using the net asset value per unit at the start and end of the relevant period in AUD, with distributions reinvested, and net of applicable fees, costs and taxes (other than tax paid as an investor in the Fund).  The returns also do not reflect the transaction costs imposed on the creation and redemptions of Units, brokerage or spreads incurred by investors when buying or selling units on the ASX. 1 Inception is 5 November 2018. 2 Benchmark is MSCI All Country World Net Index in AUD.

Performance chart

Cumulative performance (over selected time horizon)

Past performance is not a reliable indicator of future performance. Returns are calculated using the net asset value per unit at the start and end of the relevant period in AUD, with distributions reinvested, and net of applicable fees, costs and taxes (other than tax paid as an investor in the Fund).  The returns also do not reflect the transaction costs imposed on the creation and redemptions of Units, brokerage or spreads incurred by investors when buying or selling units on the ASX.  Inception is 5 November 2018.  Benchmark is MSCI All Country World Net Index in AUD.

Antipodes Global Shares (Quoted Managed Fund) - Unit Prices

Antipodes Global Shares (Quoted Managed Fund) - Distributions

Distribution reinvestment plan

The Antipodes Global Shares (Quoted Managed Fund) Distribution Reinvestment Plan (“DRP”) provides investors with an optional and convenient service to acquire additional units in the Fund by reinvesting all or part of their 30 June annual distribution.

Key information summary

  • Your distributions on units of the Fund will be subject to the DRP and will be automatically reinvested in new units in the Fund unless you make an election to the contrary.
  • The issue price of units issued or transferred under the DRP will be the net asset value per Fund unit applicable to 30 June; or such other price as determined by the RE from time to time.
  • The number of DRP units acquired under the DRP will be based on the issue price per unit and rounded down to the nearest whole unit.
  • A statement will be sent to you as soon as practicable after each distribution payment, giving full details of your units reinvested.
  • You may change your level of participation or cancel your participation in the DRP at any time and from time to time, provided sufficient notice is given (in accordance with the DRP Rules contained herein).
  • Units in the Fund issued under the DRP rank equally with existing units of the Fund from the date of issue

ASX announcements

Monthly updates

For historical reports, please contact the Antipodes team

Quarterly updates

For historical reports, please contact the Antipodes team

Financial Statements

Research Reports

Request for the latest research rating reports here

Top 10 equity longs (%)

Sector exposure (%)²

Currency exposure (%)¹ ²

Regional exposure (%)¹ ²

1 Where possible, regions, countries and currencies classified on a look through basis. 2 Antipodes Partners classification.

Invest in AGX1

Antipodes Global Shares (Quoted Managed Fund) is an active ETF quoted on the ASX (ASX: AGX1).

This means you can buy and sell units in AGX1 through your online trading account or via your broker or licensed adviser in the same way that you trade shares in other ASX-listed companies.

You can view your AGX1 unitholding alongside any other direct shareholding you have.

Unitholder enquiries

As AGX1 is a quoted security, unitholders details are recorded by the unit registry, Automic Pty Limited. If you have any queries in relation to your unitholding, please contact Automic on 1300 902 587 (within Australia) or +61 2 7208 4521 (international) or via email: hello@automic.com.au

Update your AGX1 unitholding information

To allow us to communicate with you electronically and pay any distributions to your nominated bank account, we encourage you to confirm and update your details by visiting www.investor.automic.com.au.

To login for the first time, you will need your HIN or SRN number which can found on your holding statement. Please be sure to add your email address, phone number and banking instructions as all distributions will be paid via Electronic Funds Transfer.

Equity Mates: What is pragmatic value?

Firstlinks: Jacob Mitchell on his biggest investing lessons

AGX1 Webinar: Outlook for global equities in 2022 and beyond

Ratings

Antipodes Global Shares (Quoted Managed Fund) has been rated “Recommended” by Zenith Investment Partners, “Recommended” by Lonsec Research, received a Morningstar Analyst RatingTM of “Bronze” and has a “1st Quartile” Evergreen Responsible Investment Grading Index (ERIG) ranking.

 

               

 

Important information

All website content in respect of the Antipodes Global Shares (Quoted Managed Fund) (ARSN 625 560 269) (the Fund) is issued by Pinnacle Fund Services Limited ABN 29 082 494 371 AFSL 238 371 (“PFSL”) as responsible entity of the Fund and is prepared by Antipodes Partners Limited (ABN 29 602 042 035) (AFSL 481580) (“Antipodes”) as the investment manager of the Trust. PFSL is not licensed to provide financial product advice.

The information provided in this website is of a general nature only and has been prepared without taking into account your objectives, financial situation or needs. Before making an investment decision in respect of the Fund, you should consider the current product disclosure statement (PDS) and Target Market Determination (‘TMD’) of the Fund and the Fund’s other periodic and continuous disclosure announcements lodged with the ASX, which are available at www.asx.com.au, and assess whether the Fund is appropriate given your objectives, financial situation or needs. If you require advice that takes into account your personal circumstances, you should consult a licensed or authorised financial adviser.

Neither PFSL nor Antipodes guarantees repayment of capital or any particular rate of return from the Fund. Neither PFSL nor Antipodes gives any representation or warranty as to the currency, reliability, completeness or accuracy of the information contained in this website. All opinions and estimates included in this website constitute judgments of Antipodes as at the date of website creation and are subject to change without notice. Past performance is not a reliable indicator of future performance.

The Zenith Investment Partners (ABN 27 103 132 672, AFS Licence 226872) (“Zenith”) rating (assigned Antipodes Global Fund; Antipodes Global Fund – Long; Antipodes Asia Fund – November 2020; Antipodes Global Shares (Quoted Managed Fund) – October 2020) referred to on this website is limited to “General Advice” (s766B Corporations Act 2001) for Wholesale clients only. This advice has been prepared without taking into account the objectives, financial situation or needs of any individual, including target markets of financial products, where applicable, and is subject to change at any time without prior notice. It is not a specific recommendation to purchase, sell or hold the relevant product(s). Investors should seek independent financial advice before making an investment decision and should consider the appropriateness of this advice in light of their own objectives, financial situation and needs. Investors should obtain a copy of, and consider the PDS or offer document before making any decision and refer to the full Zenith Product Assessment available on the Zenith website. Past performance is not an indication of future performance. Zenith usually charges the product issuer, fund manager or related party to conduct Product Assessments. Full details regarding Zenith’s methodology, ratings definitions and regulatory compliance are available on our Product Assessments and at Fund Research Regulatory Guidelines.

The Lonsec Ratings (assigned as follows: Antipodes Global Fund; Antipodes Global Fund – Long; Antipodes Asia Fund; Antipodes Global Shares (Quoted Managed Fund) – March 2021) presented on this website are published by Lonsec Research presented in this document are published by Lonsec Research Pty Ltd ABN 11 151 658 561 AFSL 421445. The Ratings are limited to “General Advice” (as defined in the Corporations Act 2001 (Cth)) and based solely on consideration of the investment merits of the financial products. Past performance information is for illustrative purposes only and is not indicative of future performance. They are not a recommendation to purchase, sell or hold Antipodes products, and you should seek independent financial advice before investing in these products. The Ratings are subject to change without notice and Lonsec assumes no obligation to update the relevant documents following publication. Lonsec receives a fee from the Fund Manager for researching the products using comprehensive and objective criteria. For further information regarding Lonsec’s Ratings methodology, please refer to our website at: https://www.lonsec.com.au/fund-manager/investment-product-ratings.

© 2021 Morningstar, Inc. All rights reserved. Neither Morningstar, its affiliates, nor the content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice or ‘class service’ have been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Ltd, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. Refer to our Financial Services Guide (FSG) for more information at https://www.morningstar.com.au/s/fsg.pdf. You should consider the advice in light of these matters and if applicable, the relevant Product Disclosure Statement (Australian products) or Investment Statement (New Zealand products) before making any decision to invest. Our publications, ratings and products should be viewed as an additional investment resource, not as your sole source of information. Past performance does not necessarily indicate a financial product’s future performance. To obtain advice tailored to your situation, contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Ltd ACN 004 523 782 (“ASXO”).

As at 10 May 2021 the Morningstar Analyst RatingTM for the Antipodes Global Shares (Quoted Managed Fund) (ASX:AGX1) is ‘Bronze’. As at 3 May 2021 the Morningstar Analyst RatingTM for the Antipodes Global Fund – Long is ‘Bronze’. As at 4 May 2021 the Morningstar Analyst RatingTM for the Antipodes Global Fund is ‘Neutral’.

Evergreen Research Pty Ltd trading as ERIG Index ABN 17 647 506 590 is AuthorisedRepresentative 001289533 of Evergreen Fund Managers Pty Ltd ABN 75 602 703 202AFSL 486275. The material is for the information purposes of non-retail clients only.It is not, and is not to be construed as, advice or a recommendation to acquire, holdor dispose of financial products or to use financial services. The ERIG Indexmeasures only the Responsible Investment capabilities of funds. It does not assessthe performance or other features of the funds.